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Infections during first-line therapy for DLBCL are often associated with chemotherapy dose 
reductions and increased mortality. Systemic infections have also been suggested as beneficial 
promotors of immunological responses. However, whether there is an association between the 
timing of an infectious episode and outcome during treatment has not yet been clarified. We 
investigated how the occurrence and timing of infectious episodes during the 1st line of 
treatment for ‘de novo’ DLBCL influenced patient outcome. 
We used data on DLBCL patients from the Danish Lymphoma Registry, the Danish National 
Patient Registry and the Danish National Pathology Registry. Infections were categorized 
according to type (ICD-10) and time of occurrence after treatment start. 'Early' infections were 
defined as occurring between days 7-42 and 'late' infections between days 100-150 from 
treatment start. Patients experiencing both 'early and late' infections, were categorized 
separately. We used multivariable Cox regression and Kaplan-Meier estimates to assess the 
association between infections and survival adjusting for NCCN-IPI, sex, comorbidity, and 
rituximab treatment. We identified 3,546 patients, median age 65 years (IQR 56;73). Infectious 
episodes occurred in 1,171 (33%) patients, of which 666 had 'early', 303 'late', and 202 both 
'early and late' events. Patients without registered infections had a 5-year overall survival (OS) 
rates of 74%. Those with ‘early’, ‘late’, or 'early+late' had 5-year OS of 65%, 62%, and 53%, 
respectively. Compared with patients without any registered infections, hazard rate ratios (HR) 
were 1.24 (95% CI 1.05-1.47), 1.32 (95% CI 1.06-1.63) and 1.59 (95% CI 1.27-2.00), respectively 
in the multivariable model.  
We observed that infectious episodes during first line-treatment for 'de novo' DLBCL occurred 
in 44% of the patients. Irrespective of timing, patients with infectious episodes had an inferior 
outcome compared to those without. Outcome patterns was similar for patients registered 
with sepsis. 
  













Treatment with cytotoxic chemo-immunotherapy has, besides an intended tumoricidal effect, 
also an unintended toxic side effect on the tissues and cells of both the innate and the adaptive 
immune system.(1,2) Well recognized common toxicities include mucosal barrier injury and 
neutropenia, which jointly set the stage for infectious complications.(3–5) Febrile neutropenia 
and sepsis are among the most common clinical syndromes associated with hospitalization in 
cancer patients undergoing chemotherapy and are known to negatively impact outcome.(6) 
This is especially true in elderly and/or otherwise frail patients e.g. those with comorbid 
conditions.(7,8) On the other hand, spontaneous regressions of malignant lesions observed 
after acute febrile/septic episodes have been described and are suggested to reflect an 
activation of anti-tumoral effects from the host's immune system such as chimeric antigen 
receptor (CAR) T-cell therapy and check point protein modulation.(9–15) In terms of timing, 
most existing studies show that the majority of infectious complications, recorded under 
induction chemotherapy for DLBCL, occur early in the course of treatment and most frequently 
after the first cycle.(8,16,17) 
To elucidate, whether the occurrence of an infectious episode and its timing ('early', 'late' or 
'early and late') during first-line therapy for DLBCL has an impact on outcome, we investigated a 
nationwide, population-based cohort of 3,546 'de novo' DLBCL patients identified through the 
Danish Lymphoma Registry. 
Methods 
Setting 
Denmark has a population of approximately 5.7 million inhabitants and all residents have 
access to free tax-supported health care. More specifically, cancer therapy, including 












supportive care and medicine (e.g. antibiotics, growth factors and immunoglobulins), is free of 
cost.  
Registries 
Danish registries are unique in term of quality, coverage and completeness and they reflect the 
health care utilization of the population on a nationwide level.(18) We used four nationwide 
Danish medical databases to conduct this population-based cohort study: (i) the Civil 
Registration system (CRS), (ii) the Danish National Patient Registry (DNPR), (iii) the Danish 
Lymphoma Registry (LYFO), and (iv) the Danish National Pathology Registry. The CRS uses a 
unique 10-digit Civil Persons Register (CPR) number, assigned to every citizen upon birth or 
immigration and this number is a key component of register-based research in Denmark, since 
it serves as the common identifier that allows cross-linkage across all Danish medical and 
administrative registers and clinical databases.(19,20) Data on vital status were obtained from 
the CRS, where this data is updated on a daily basis for all Danish citizens.(21) Information on 
the occurrence of diagnoses of infection was obtained from the DNPR, which is a 
comprehensive nationwide hospital register recording, for each citizen, every contact with the 
hospital system along with parameters such as primary diagnosis, treatments given, and 
paraclinical examinations performed (e.g. blood tests and diagnostic imaging).(22,23) 
Lymphoma-specific information was retrieved from the LYFO-registry, which prospectively 
registers patients with lymphoid malignancies, referred to the lymphoma-treating hematology 
departments in Denmark. LYFO includes 95% of all lymphoma patients in Denmark and has a 
completeness of registered variables of 99%, and positive predictive values for variables 
ranging from 88% to 99%.(24) Variables contained in the LYFO registry include lymphoma 
histology (according to The International Classification of Disease for Oncology third edition 












histology codes [ICD-O-3]), date of diagnosis, Ann Arbor stage, paraclinical findings, 
International Prognostic Index (IPI), antineoplastic treatment, response to therapy etc.(25) 
Pathology reports for all patients were retrieved from the Danish National Pathology Registry, 
which contains detailed descriptions of all pathology specimens analyzed in Denmark since 
1997. This register is also used to identify those very few lymphoma patients that are not 
captured by the LYFO registry.(26) 
Patients and covariates 
From LYFO we included patients diagnosed with ‘de novo’ DLBCL, between January 1, 2000 
and December 31, 2012, that had been treated with anthracycline containing chemotherapy 
with or without rituximab. Patients were excluded if they had a diagnosis of primary central 
nervous system (CNS)-lymphoma, if lymphoma was diagnosed at autopsy or if information on 
antineoplastic therapy was missing. From the LYFO registry, we extracted baseline patient 
characteristics including information on sex, age, Ann Arbor stage, extra nodal disease, plasma 
lactate dehydrogenase (LDH), Eastern Cooperative Oncology Group (ECOG) performance 
status, and treatment regimens. Furthermore, we identified date of diagnosis, first treatment, 
and where applicable, clinical relapse and start of relapse treatment. Pathology reports of the 
primary as well as the relapse biopsies from all patients were obtained from the Danish 
National Pathology Registry and were used to cross-validate the date of diagnosis. The 
Pathology Registry was also used to confirm whether a bone marrow biopsy actually was 
performed and, if so, whether it showed lymphoma infiltration. For relapse biopsies, we 
obtained information on the biopsy date and relapse histology. To assess the level of 
comorbidity, a Charlson Comorbidity Index (CCI) was computed based on DNPR diagnoses 
recorded up to ten years before the onset of DLBCL.(27) We used the nineteen diagnoses from 












the original CCI publication and defined three levels of comorbidity: CCI score 0 (No 
comorbidity), 1-2 (moderate) or >2 (severe). DNPR data for assessment of comorbidity has 
been validated for the time period covering this study.(28) The National Comprehensive 
Cancer Network International Prognostic Index (NCCN-IPI) was calculated as described in the 
original publication.(29) This prognostic index includes the same covariates as the original IPI 
(age, ECOG performance status, serum lactate dehydrogenase level, extra nodal sites and Ann 
Arbor stage).(30) In addition, the NCCN-IPI refines age in four age strata (≤40, 41-60, 61-75, 
>75 years), LDH in three strata (LDH-ratio≤1, LDH-ratio>1-3 and LDH-ratio>3), and it uses 
information on extra nodal disease from four specified sites, i.e. bone marrow, CNS, 
liver/gastrointestinal tract and lung. 
Exposure 
From the DNPR we obtained information date and duration of admissions with a primary 
diagnosis of infection according to the International Classification of Diseases 10th revision 
(ICD-10)(see Table S2 for codes).(22,23) We restricted our search to admissions for infection 
with a duration of at least 24 hours to secure that the infection had a certain level of 
seriousness. Infections were categorized according to day of admission in the treatment 
period. Infection was defined as ‘early’ if the admission with infection was registered between 
days 7-42 and 'late', if it occurred between days 100-150. The definition of ‘early’ infections as 
those occurring between days 7 and 42 from treatment start, reflects the period from the first 
potential nadir (day 7, e.g. in a bi-weekly R-CHOP schedule) to the start of the 3rd course (day 
42, e.g. in a tri-weekly R-CHOP schedule). Similarly, the definition of ‘late’ infectious episodes 
reflects the period after the start of the 6th course until the end of the nadir after the 8th 
course (day 150, e.g. in a tri-weekly R-CHOP x 8 schedule). Patients with infectious episodes 
which occurred both early and late were categorized as a separate group. Based on the 












diagnosis codes, we classified the infectious diagnoses into eleven categories reflecting organ 
involvement, major clinical syndromes and clinical severity. The eleven categories were: 
Febrile neutropenia, sepsis, pneumonia, infections of the CNS, upper airway infections, 
gastrointestinal and urinary tract infections, infections of the skin- and other soft tissues, 
mouth infections, unspecified fever, and other infectious conditions (Table S2). The eleven 
categories were also used to register the more serious infection if a patient had more than 
one diagnose of infection registered on discharge, i.e. sepsis was used instead of skin infection 
if both were registered. In a sensitivity analysis, considering a severe and prevalent infection, 
we examined the outcomes for patients registered with sepsis. 
Statistics 
Baseline demographics are presented as counts and percentages for all patients and according 
to the time period of infection (early, late, early and late, or none). Data on continuous 
variables are presented as median and inter quartile range (IQR). Each category of infection and 
the total count among patients are presented according to time periods. We used the Kaplan-
Meier method and Cox proportional hazards regression analysis to assess the association of 
occurrence and timing of episodes of infection with overall survival (OS) and event free survival 
(EFS), patients without infection were used as reference.(31,32) In order to avoid immortal 
time bias patients were followed from 150 days after diagnosis to death from any cause (OS), 
while EFS was measured as time to relapse, retreatment registered by the clinician with or 
without biopsy, or death. We adjusted for NCCN-IPI (4 groups), sex, rituximab treatment 
(yes/no), and level of comorbidity (3 groups). We also conducted analyses stratified by sex, age 
(<61 vs≥61 years) and rituximab treatment (yes/no). All estimates were calculated with 95% 
confidence intervals (95%CI). The proportional hazards assumption was evaluated graphically 
with log minus log plots and was accepted. We used the STROBE statement to guide the 












reporting of our study.(33) 
Statistical analyses were performed using Stata/IC 14.2 (Stata Statistical Software: Release 14. 
College Station, TX: StataCorp LP). This study was approved by the Danish Data Protection 
Agency (1-16-02-562-13) and the Danish Health and Medicines Authority (3-3013-1079/1/).  
Results 
We identified 3,546 patients (Figure 1) who fulfilled the inclusion criteria. Patients had a 
median age of 65 years (quartiles 56;73) and 56% were men. Detailed patient characteristics 
are shown in Table 1 for all patients and Table S4 for patients in the survival analysis. In total, 
1,551 (44%) patients had at least one infection registered within 150 days from beginning their 
treatment; 666 (19%) patients had an early infection, 303 (9%) a late,  202 (6%) both an early 
and a late infection . In the time period between early and late 380 (11%) patients had an 
episode of infection registered. Patients with ‘only early’ or ‘only late’ infection had a similar 
distribution of NCCN-IPI score, sex, and comorbidity index, while patients with ‘both early and 
late’ infection more often had advanced disease with extranodal involvement, poor 
performance status, elevated LDH, and a higher CCI score. Patients receiving rituximab 
treatment constituted 75% of the total cohort reflecting the time period of the study. Within 
the ‘early’ infection group, the fraction of rituximab treated patients was slightly higher (82%) 
than the one of the ‘late’ and ‘early + late’ infection groups (76% and 79%, respectively). Figure 
S1 illustrates the time periods investigated. Table 2 displays the categories of the first infection, 
both in total and according to the timing in the course of treatment (early, late or early + late. 
The 1,171 patients had a total of 1,641 infections, 821 (70.1%) patients had one, 253 (21.6%) 
two, 77 (6.6%) three, and the remaining 20 patients had four or more diagnoses of infection 
recorded in the DNRP (Table S3). Febrile neutropenia (34%), septicemia (17%), and pneumonia 
(14%) were the most common categories of infection both in the case of early and of later 












infections. Among the patients with septicemia, 77% were registered with unspecified sepsis, 
and 7% with sepsis due to gram-negative infection (Table S2).  
Survival 
Within the first 150 days, 373 patients died. At a median follow-up time of 7.9 years, 942 (30%) 
died and 1,134 (34%) had a relapse registered, with or without biopsy, or died. As shown in 
Table 3 and figure 2, patients without registered infectious episodes had a 5-year OS probability 
of 74% (95% CI 72-75). In comparison, those with ‘early’, late and early+late infections had a 5-
year OS probability of 65% (95% CI 61-69), 62% (95% CI 56-68), and 53% (95% CI 45-60), 
respectively, with corresponding adjusted hazard rate ratios of 1.24 (95% CI 1.05-1.47), 1.32 
(95% CI 1.06-1.63) and 1.59 (95% CI 1.27-2.00). The results of the stratified analysis revealed 
that infection was associated with an increased mortality, particularly for women, as shown in 
Figure 3 and Table S1. However, patients younger than 60 years with early infection tended to 
have a superior outcome, HR 0.93 (95% CI 0.64-1.36) compared to patients without infection, 
but the CI is broad due to small numbers. Furthermore, patients treated with CHOP did not 
have inferior outcome if infection was registered. In a sensitivity analysis looking at patients 
registered with an episode of sepsis, we observed a similar pattern of outcome as in patients 
with registered infection overall. The group without sepsis had the best outcome, early and late 
had intermediate outcomes, and patients with sepsis in both time periods had the worst 
outcome (Figure S2). 
Discussion 
In this nationwide study of ‘de novo’ DLBCL patients, we found that patients with infection, no 
matter the time period, had an inferior outcome compared to those without. Therefore, our 
data do not support the hypothesis of a possible beneficial anti-tumoral role of an infection 
early or late during the treatment of DLBCL. We found that one third of the patients had a 












diagnose of infection registered in a cumulated period of 85 days during treatment and 44% 
during the first 150 days. The observation that early infection in patients 60 years or younger 
has a HR of 0.93 was based on few observations with a correspondingly wide confidence 
interval and does not, as a single observation, confirm our hypothesis, and could represent a 
chance finding. The negative impact on outcome was pronounced in patients above 60-years. 
Older age has in several studies proved to be a risk factor for infection and the EORTC 
recognizes age above 60 years as a an important risk factor for febrile neutropenia.(34) Also in 
rituximab treated patients both early and late infection had a negative prognostic impact and 
we observed that rituximab treated patients with both early and late infections had a 
particularly low 5 year OS. A possible explanation could be that rituximab eliminates the 
healthy CD20-positive lymphocyte population resulting in decreased concentration of 
immunoglobulins with a consequent increased risk of infection.(35,36) A further contribution 
to this observation may be the increasing dose intensity given to elderly patients with DLBCL 
in more recent years. We recently showed that anthracycline containing therapy was 
administered in 71% of patients above 74 years, in the period from 2008 to 2012, compared to 
only 57% between 2003 and 2007.(37) The more frequent use of anthracyclines in patients 
above 74 years seen in recent years probably reflects a combination of factors, such as a more 
fit elderly population, better supportive strategies and a consequent shift towards a more 
curatively intended approach in the elderly.  
The strengths of this study include the population-based design with an almost complete 
prospective inclusion of all DLBCL patients treated with curative intent in Denmark over a 
recent 12-year period with well-covered long-term follow-up. Patients have unfettered access 
to cancer treatment and follow-up programs in the public health care system including access 
to hospitals in case of infectious complications and no private practice of cancer treatment 












exists in Denmark. This virtually eliminates a selection towards more healthy patients into our 
cohort. The LYFO registry has recently been validated and showed high completeness and 
positive predictive values for selected variables above 95%.(24) One of the limitations of our 
study was the lack of validation of the registered infection diagnoses. However, the incidence 
of infections in our study is in accordance with observations from both randomized clinical 
trials (RCT) and observational data, where occurrence of grade 3 or 4 infections range from 
around 20% in RCTs and 50% in observational studies.(2,38–41) Moreover, a recent validation 
study showed that the positive predictive value of an infection diagnosis in cancer patients 
registered in the DNPR ranged from 84% for ‘sepsis’ to 93% for ‘pneumonia’.(42) We included 
only admissions with infection lasting more than 24 hours as infectious admissions to secure 
that the included infections had a certain degree of seriousness. It is possible that some 
admissions lasting more than 24 hours, which accordingly were categorized as “no infection” 
also were serious infections which would bias our estimates towards no difference. The 
proportion of patients registered with infection in our study, however, argues against a high 
degree of misclassification. Another limitation lies in the somewhat arbitrary definition of 
‘early’ and ‘late’ occurrence, considering the heterogeneity of treatment timelines reflected 
by e.g. patients who received chemoimmunotherapy on a bi- or tri-weekly basis or patients 
who had their treatment schedule delayed by excessive toxicities.  
Conclusion 
This is, to our knowledge, the largest study examining the prognostic impact of register-based 
infections in DLBCL patients within the rituximab era. We conclude that infectious episodes 
did not seem to have an antineoplastic effect translating into a survival advantage for DLBCL 
patients. DLBCL patients in general, and elderly DLBCL patients in particular, face a high risk of 
therapy-related infections, and the adverse impact on outcome from these complications 












seem to add prognostic information to well-established prognosticators such as NCCN-IPI and 
the Charlson Comorbidity Index. These findings provide an insight and a rationale for tailoring 
adjuvant supportive approaches such as antimicrobial prophylaxis, use of growth factors and 
immunoglobulin substitution, particularly in elderly patients.  
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Table 1.Baseline patient characteristics 
 None Early Late Early and late Total 
 N    % N    % N    % N    % N    % 
All 2,375 (100) 666 (100) 303 (100) 202 (100) 3,546 (100) 
Sex           
Women 1,019 (43) 309 (46) 144 (48) 96 (48) 1,568 (44) 
Men 1,356 (57) 357 (54) 159 (52) 106 (52) 1,978 (56) 
Age      
Median age in years (IQR)  64 (55;72) 68 (59;76) 65 (55;73) 65 (58;74) 65 (56;73) 
≤40 years 172 (7) 42 (6) 30 (10) 13 (6) 257 (7) 
41-60 years 766 (32) 160 (24) 78 (26) 50 (25) 1,054 (30 
61-75 years 1,034 (44) 294 (44) 136 (45) 101 (50) 1,565 (44) 
>75 years 403 (17) 170 (26) 59 (19) 38 (19) 670 (19) 
Ann Arbor stage           
I-II 1,123 (47) 264 (40) 108 (36) 58 (29) 1,553 (44) 
III-IV 1,252 (53) 402 (60) 195 (64) 144 (71) 1,993 (56) 
Lactate dehydrogenase (× ULN)          
LDH-R ≤1 1,183 (50) 261 (39) 126 (42) 67 (33) 1,637 (46) 
LDH-R >1-3 951 (40) 329 (49) 139 (46) 116 (57) 1,535 (43) 
LDH-R >3 170 (7) 62 (9) 27 (9) 16 (8) 275 (8) 
Missing 71 (3) 14 (2) 11 (4) 3 (1) 99 (3) 
Performance (ECOG)           
0-1 1,979 (83) 493 (74) 227 (75) 151 (75) 2,850 (80) 
≥2 378 (16) 170 (26) 75 (25) 50 (25) 673 (19) 
Missing 18 (1) 3 (<1) 1 (<1) 1 (<1) 23 (1) 
Extra nodal disease           
Not present 1,616 (68) 399 (60) 185 (61) 108 (53) 2,308 (65) 
Present 759 (32) 267 (40) 118 (39) 94 (47) 1,238 (35) 
NCCN-IPI           
Low risk 335 (14) 46 (7) 21 (7) 5 (2) 407 (11) 
Low– Intermediate risk 973 (41) 226 (34) 111 (37) 68 (34) 1,378 (39) 
High-Intermediate risk 768 (32) 278 (42) 126 (42) 97 (48) 1,269 (36) 
High risk 221 (9) 101 (15) 34 (11) 29 (14) 385 (11) 
Missing 78 (3) 15 (2) 11 (4) 3 (1) 107 (3) 
Charlson Comorbidity Index           
None 1,469 (62) 333 (50) 168 (55) 92 (46) 2,062 (58) 
Moderate 649 (27) 239 (36) 100 (33) 71 (35) 1,059 (30) 
Severe 257 (11) 94 (14) 35 (12) 39 (19)  425 (12) 
Treatment           
Chemo 662 (28) 118 (18) 73 (24) 43 (21) 896 (25) 
R-chemo 1,713 (72) 548 (82) 230 (76) 159 (79) 2,650 (75) 
Infection day 43-100           
No 1,995 (84) 425 (64) 209 (69) 85 (42) 2,714 (77) 
Yes 380 (16) 241 (36) 94 (31) 117 (58) 832 (23) 
Abbreviations: IQR interquartile range; LDH lactate dehydrogenase; ULN upper level of normal; ECOG Eastern 
cooperative oncology group; NCCN National Comprehensive Cancer Network; IPI International Prognostic Index; R 
rituximab 
  












Table 2.Types of infection by time period 
Category of infection Early Late Early and late Total 
       N   % N   % N   % N   % 
Febrile neutropenia 247 (37) 75 (25) 74 (37) 396 (34) 
CNS infection 1 (<1) 0 (0) 0 (0) 1 (<1) 
Septicemia 109 (16) 49 (16) 40 (20) 198 (17) 
Pneumonia 86 (13) 52 (17) 23 (11) 161 (14) 
Upper respiratory 
infection 
7 (1) 9 (3) 3 (1) 19 (2) 
GI infections 28 (4) 11 (4) 9 (4) 48 (4) 
Urinary tract infections 34 (5) 17 (6) 8 (4) 59 (5) 
Mucositis 17 (3) 9 (3) 3 (1) 29 (2) 
Skin infections 30 (5) 27 (9) 6 (3) 63 (5) 
Fever, not specified 90 (14) 46 (15) 31 (15) 167 (14) 
Other 17 (3) 8 (3) 5 (2) 30 (3) 
















Table 3. Crude and adjusted† HRs for overall survival and event free survival for all patients 
 
 5-year OS OS unadjusted OS adjusted 5-year EFS EFS unadjusted EFS adjusted 
Infection N % 95% CI HR 95%CI HR 95%CI % 95%CI HR 95% CI HR 95%CI 
None 2,134 74 72-75 1.00 Ref. 1.00 Ref. 67 65-69 1.00 Ref. 1.00 Ref. 
Early 560 65 61-69 1.44 1.22-1.69 1.24 1.05-1.47 61 57-75 1.26 1.08-1.47 1.14 0.98–1.34 
Late 288 62 56-68 1.61 1.31–1.98 1.32 1.06–1.63 55 49-61 1.55 1.28-1.87 1.30 1.07–1.59 
Early and late 191 53 45-60 2.19 1.75–2.74 1.59 1.27–2.00 48 41-55 1.91 1.55–2.36 1.44 1.16–1.79 
†
Adjusted for NCCN-IPI, comorbidity, sex and rituximab. A total of 459 patients were not included in the adjusted model; 
missing values in 86 pts and 373 died before day 150 
Abbreviations: OS overall survival; EFS event free survival; HR hazard rate ratios; Ref reference; NCCN-IPI National 
Comprehensive Cancer Network International Prognostic Index 
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